Is aspirin "the weakest link" in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease

Progress in Cardiovascular Diseases

Volumn 44, Issue 4, 2002, Pages 275-292

  Cleland, John G F ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; WARFARIN;

ACUTE DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL OBSERVATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; DYSPEPSIA; EXTRASYSTOLE; GASTROINTESTINAL HEMORRHAGE; HEART VENTRICLE ARRHYTHMIA; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; META ANALYSIS; PEPTIC ULCER; PRESCRIPTION; PROPHYLAXIS; REVIEW; RISK BENEFIT ANALYSIS; VASCULAR DISEASE;

EID: 0036228408     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2002.31597     Document Type: Article

References (125)

1. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients
2. Clinical pharmacology of platelet cyclooxygenase inhibition
3. Even low-dose aspirin inhibits arachidonic acid-induced vasodilatation in heart failure
4. Dose-related kinetics of aspirin
5. Aspirin causes short-lived inhibition of bradykinin-stimulated prostacyclin production in man
6. Prothrombotic effects of erythrocytes on platelet reactivity
7. The importance of aspirin dose in the protection of non-haemorrhagic stroke following acute myocardial infarction: Insights from the coumadin aspirin reinfarction study (CARS)
8. Enhanced basal nitric oxide production in heart failure: Another failed counter regulatory vasodilator mechanism?
9. Plasma alpha natriuretic peptide in cardiac impairement
10. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia
11. Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril
12. Endothelium-dependent modulation of responses to endothelin-1 in human veins
13. Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure
14. Bradykinin and ventricular function
15. Sudden death in heart failure: Vascular or electrical?
16. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril. Results of a double-blind, randomised comparative trial
17. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure
18. Is aspirin safe for patients with heart failure?
19. Anticoagulant and antiplatelet therapy in heart failure
20. Aspirin does not inhibit the vasodilating effects of enalapril in the skeletal muscle circulation of patients with heart failure
21. Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with Enalapril
22. Redistribution of regional blood flow following ACE inhibition: Comparison of normal subjects and patients with heart failure
23. Hemodynamic and regional blood flow response to captopril in congestive heart failure
24. Effect of long-term angiotensin-converting enzyme inhibition on vascular function in patients with chronic congestive heart failure
25. Effects of acetylsalicylic acid on renal function in patients with chronic heart failure
26. Antagonistic effect of non-steroidal anti-inflammatory drugs on frusemide-induced diuresis in cardiac failure
27. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. An underrecognised public health problem
28. NSAIDs associated with risk of congestive heart failure in elderly patients taking diuretics
29. Renal syndromes associated with non-steroidal anti-inflammatory drugs
30. Persantine and aspirin in coronary heart disease
31. Persantine-Aspirin Reinfarction Study. Part II Secondary coronary prevention with persantine and aspirin
32. A randomised, controlled trial of aspirin in persons recovered from myocardial infarction
33. The aspirin myocardial infarction study: Final results
34. Worsening of morbidity and renal function in angiotensin-converting enzyme- inhibited heart failure patients taking aspirin
35. Combined effect of captopril and aspirin on renal haemodynamics in elderly patients with congestive heart failure
36. Combining salicylate and enalapril in patients with coronary artery disease and heart failure
37. Update on the interaction between aspirin and angiotensin-converting enzyme inhibitors
38. Meeting report - LIDO, HOPE, MOXCON and WASH Studies
39. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin
40. Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction
41. The detrimental effect of combined aspirin and angiotensin converting enzyme inhibitor therapy on readmission rates in heart failure
42. Modulation of alveolar-capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by Iosartan, in chronic heart failure
43. Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors
44. Angiotensin-converting enzyme inhibition restores the diffusing capacity for carbon monoxide in patients with chronic heart failure by improving the molecular diffusion across the alveolar capillary membrane
45. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin
46. Reduced alveolarcapillary membrane diffusing capacity in chronic heart failure: Its pathophysiological relevance and relationship to exercise performance
47. Impaired pulmonary diffusion during exercise in patients with chronic heart failure
48. COX provides missing link in mechanism of aspirin in colon cancer
49. Stimulation of apoptosis by sulindac and piroxicam
50. Aspirin use and colorectal cancer: Post-trial follow-up data from the US Physician's Study
51. Myocardial infarction and coronary deaths in the World Health Organisation MONICA project
52. Mortality and morbidity in patients receiving encainide, flecainide, or placebo - The Cardiac Arrhythmia Suppression Trial
53. Interaction of ischaemia and encainide/flecainide treatment: A proposed mechanism for the increased mortality in CAST I
54. Effect of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial
55. Incidence and prognosis of unrecognised myocardial infarction: An update on the Framingham Study
56. Prevalence, clinical characteristics and mortality among patients with myocardial infarction presenting without chest pain
57. The promise and problems of meta-analysis
58. Meta-analysis under scrutiny
59. Bias in meta-analysis detected by a simple graphical test
60. Meta-analysis of randomised controlled trials
61. Relative role of meta-analysis and randomised controlled trials in the assessment of medical therapies
62. Secondary prevention of vascular disease by prolonged anti-platelet treatment
63. Collaborative overview of randomised trials of antiplatelet therapy - 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
64. Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients
65. Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy
66. The European stroke prevention study
67. The German-Austrian aspirin trial: A comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction
68. A randomised controlled trial of aspirin in the prevention of early mortality in myocardial infarction
69. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction
70. Persantine and aspirin in coronary heart disease
71. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1
72. Protective effects of aspirin against acute mycardial infarction and death in men with unstable angina
73. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
74. Aspirin (75mg/day) after an episode of unstable coronary artery disease: Long-term effects on the risk ofor myocardial infarction, occurrence of severe angina and the need for revascularisation
75. CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke
76. The International Stroke Trial (IST) A randomised trial of aspirin, subcutaneous haperin, both, or neither among 19,435 patients with acute ischaemic stroke
77. Clinical trials in stable and unstable angina
78. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice
79. Final report on the aspirin component of the ongoing physician's health study
80. Thrombosis prevention trial: Randomised trial of low-density oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk
81. Randomised trial of prophylactic daily aspirin in British male doctors
82. Aspirin use and chronic diseases: A cohort study of the elderly
83. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial
84. Aspirin in coronary heart disease
85. Prevention of reinfarction with acetylsalicylic acid
86. A randomised controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction
87. Aspirin and secondary prevention after myocardial infarction
88. Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris
89. An uncommon case of fluid retention simulating a congestive heart failure after aspirin consumption
90. Effect of combined aspirin and angiotensin-converting enzyme inhibitor therapy versus angiotensin-converting enzyme inhibitor therapy alone on readmission rates in heart failure
91. Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalization for an acute myocardial infarction
92. Meeting report: LIDO, HOPE, MOXCON, and WASH studies
93. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery
94. Task force for the diagnosis and treatment of chronic heart failure: Guidelines for the diagnosis and treatment of chronic heart failure
95. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult
96. European Stroke Prevention Study
97. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
98. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results
99. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of strokes
100. Danish very-low-dose aspirin after carotid endarterectomy trial
101. What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effects of ACE inhibitors on exercise capacity
102. North of England evidence based guideline development project: Guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care
103. Long term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: A systematic overview of data from individual patients
104. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients
105. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetyl-salicylic acid. The HOT Study
106. GISSI-3: Effects of lisinopril and transdermal glyceryl binitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
107. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial
108. Aspirin use is low among United States outpatients with coronary artery disease
109. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
110. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
111. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
112. Antiplatelet agents and survival: A cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial
113. Is aspirin safe in heart failure? More data
114. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: A cohort study of 11,575 patients with coronary artery disease
115. The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials
116. Aspirin and bleeding peptic ulcers in the elderly
117. Prophylactic use of aspirin and risk of peptic ulcer bleeding
118. Peptic ulcer bleeding: Accessory risk factors and interactions with non-steroidal anti-inflammatory drugs
119. For debate: Preventing atherosclerotic events with aspirin
120. Determination of who may derive most benefit from aspirin in primary prevention: Subgroup results from a randomised controlled trial
121. Effect of ramipril and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
122. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
123. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
124. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction
125. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: Interim report from the Chinese Cardiac Study (CCS-1)